SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — May 24, 2012
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: May 24, 2012 · CIK: 0001213037 · Accession: 0001104659-12-039764
AI Filing Summary & Sentiment
File numbers found in text: 333-180810
Letter
Re: Trovagene, Inc. (the “Company”) File No. 333-180810 Registration Statement on Form S-1
AEGIS CAPITAL CORP. 810 7TH Avenue New York, New York 10019
May 24, 2012
VIA EDGAR AND TELECOPY
Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549
Ladies and Gentlemen:
We, as representatives of the several underwriters, hereby request the withdrawal of our request for acceleration, dated May 22, 2012, of the effective date of the above-referenced Registration Statement that was requested to become effective at 5:00 p.m., Washington D.C. time, on May 24, 2012, or as soon thereafter as practicable.
Very truly yours,
AEGIS CAPITAL CORP.
Show Raw Text
CORRESP
1
filename1.htm
AEGIS CAPITAL CORP.
810 7TH Avenue
New York, New York 10019
May 24, 2012
VIA EDGAR AND TELECOPY
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Trovagene, Inc. (the “Company”)
File No. 333-180810
Registration Statement on Form S-1
Ladies and Gentlemen:
We, as representatives of the several underwriters, hereby request the withdrawal of our request for acceleration, dated May 22, 2012, of the effective date of the above-referenced Registration Statement that was requested to become effective at 5:00 p.m., Washington D.C. time, on May 24, 2012, or as soon thereafter as practicable.
Very truly yours,
AEGIS CAPITAL CORP.
By:
/s/ Kevin C. McKenna
Name: Kevin C. McKenna
Title: Chief Compliance Officer